Bina Launched a New program for Drug Discovery

We announce the launch of a new track for drug discovery at Bina. This initiative aims to bring together Weizmann Institute of Science scientists and world-class experts from the pharmaceutical and drug development industries, as well as clinical practice. Harnessing Weizmann’s deep and innovative basic science research into the discovery of disease mechanisms and molecular and cellular pathways can lead to the development of new targets and therapeutic agents.

We would like to thank our SAB committee for their significant contribution: Isaac Kohlberg from Harvard University, Aya Jakobovits; Opher Shapira, CEO of YEDA and Irit Sagi, VP Innovation and Technology Transfer at the Weizmann Institute.